Janux Therapeutics (JANX) Stock Price, News & Analysis

Company Overview

Janux Therapeutics, Inc. is a clinical-stage immuno-oncology company headquartered in Cambridge, Massachusetts. Founded in 2021 by Flagship Pioneering, the company focuses on developing novel T-cell receptor (TCR) therapies to treat solid tumors. Janux has built an integrated research and development infrastructure that spans early discovery through clinical evaluation, emphasizing precision targeting of cancer antigens with engineered cell-therapy products.

At the core of Janux’s approach is its proprietary RAMP (Receptor Activation through Membrane Proximal signaling) platform, which aims to enhance TCR signaling strength, specificity, and safety. Leveraging advanced protein engineering, cell-culture technologies, and in vivo modeling, the company advances a pipeline of TCR-T candidates directed against well-characterized tumor antigens such as MAGEA4 and MAGEA10. Preclinical studies conducted at its Cambridge facility have demonstrated promising anti-tumor activity, supporting the initiation of early-phase clinical trials in multiple solid tumor indications.

Janux conducts its clinical programs across the United States and Europe through collaborations with leading cancer research centers and academic institutions. The company is led by President and Chief Executive Officer Christina Vernon, Ph.D., who brings more than 20 years of experience in oncology drug development. Janux’s executive team includes seasoned experts in cell therapy, translational research, and regulatory affairs, positioning the company to advance its TCR-T platform toward broader patient access and future combination strategies.

Key Stats

• Today's Range: $23.97 to $24.65
• 50-Day Range: $22.62 to $33.20
• 52-Week Range: $22.48 to $71.71
• Volume: 812,470 shs
• Average Volume: 864,132 shs
• Market Capitalization: $1.45 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $95.25
• Consensus Rating: Buy

Janux Therapeutics Stock Analysis - MarketRank™

Janux Therapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 751st out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Janux Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.09, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Janux Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Janux Therapeutics are expected to decrease in the coming year, from ($1.38) to ($2.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Janux Therapeutics is -17.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Janux Therapeutics is -17.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Janux Therapeutics has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

21.42% of the float of Janux Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Janux Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.

Change versus previous month

Short interest in Janux Therapeutics has recently decreased by 0.56%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Janux Therapeutics does not currently pay a dividend.

Dividend Growth

Janux Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

21.42% of the float of Janux Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Janux Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.

Change versus previous month

Short interest in Janux Therapeutics has recently decreased by 0.56%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for JANX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

3 people have added Janux Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Janux Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $206,776.00 in company stock.

Percentage Held by Insiders

29.40% of the stock of Janux Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.39% of the stock of Janux Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

JANX Stock Analysis - Frequently Asked Questions

How have JANX shares performed this year?

Janux Therapeutics' stock was trading at $53.54 on January 1st, 2025. Since then, JANX shares have decreased by 54.3% and is now trading at $24.45.

How were Janux Therapeutics' earnings last quarter?

Janux Therapeutics, Inc. (NASDAQ:JANX) released its quarterly earnings data on Thursday, May, 8th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.05.

When did Janux Therapeutics IPO?

Janux Therapeutics (JANX) raised $152 million in an initial public offering on Friday, June 11th 2021. The company issued 9,500,000 shares at $15.00-$17.00 per share. BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. LLC was co-manager.

How do I buy shares of Janux Therapeutics?

Shares of JANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Janux Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Janux Therapeutics investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC), Voyager Therapeutics (VYGR), Waste Connections (WCN) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:JANX
• CIK: 1817713
• Web: www.januxrx.com
• Phone: 858-751-4493
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Janux Therapeutics: $95.25
• High Price Target: $200.00
• Low Price Target: $41.00
• Potential Upside/Downside: +289.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.09
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$68.99 million
• Net Margins: N/A
• Pretax Margin: -832.71%
• Return on Equity: -9.29%
• Return on Assets: -8.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 58.47
• Quick Ratio: 58.47

Sales & Book Value

• Annual Sales: $10.59 million
• Price / Sales: 136.61
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $19.49 per share
• Price / Book: 1.25

Miscellaneous

• Outstanding Shares: 59,170,000
• Free Float: 41,778,000
• Market Cap: $1.45 billion
• Optionable: Optionable
• Beta: 2.86